ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Clinical trials for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to keep stomach cancer from coming back after surgery
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from returning. About 70 adults who have had their tumor removed will receive the combination treatment …
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New triple therapy shows promise in shrinking advanced stomach tumors before surgery
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (thymalfasin) to standard chemotherapy and immunotherapy can help shrink stage III stomach or gastroesophageal junction cancer before surgery. About 30 adults aged 18-75 will receive the combination, then have their tumor ti…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zekuan Xu • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo aims to boost Pre-Surgery treatment for stomach cancer
Disease control Recruiting nowThis early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for rare cancers: immunotherapy drug dostarlimab takes on chemo in phase 2 trial
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancr…
Matched conditions: ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC